The current FDA labels for Wegovy, Zepbound and Foundayo each warn about acute gallbladder disease. The Wegovy label says treatment is associated with an increased occurrence of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), and the Zepbound and Foundayo labels say the same of acute gallbladder disease. Rapid weight loss can itself raise gallstone risk, but Wegovy’s label says gallbladder events were still more frequent than with placebo even after accounting for the degree of weight loss. Pain in the upper right abdomen that lasts for hours, or comes with fever or yellowing of the skin, needs prompt medical care.
What the labels say
All three labels describe the problem in their Warnings and Precautions sections, and all say that if gallbladder disease is suspected, gallbladder studies and clinical follow-up are indicated.
The Wegovy label (revised 06/2026), section 5.3, says treatment is associated with an increased occurrence of cholelithiasis and cholecystitis. In the trial data it reports, cholelithiasis was reported by 1.6% of injection-treated patients and 0.7% of those on placebo injection, and by 2.5% of tablet-treated patients and 1% of those on placebo tablets. Cholecystitis was reported by 0.6% of injection-treated adults and 0.2% of those on placebo. The label states that substantial or rapid weight loss can increase the risk of cholelithiasis, but that the incidence of acute gallbladder disease was greater with Wegovy than placebo even after accounting for the degree of weight loss.
The Zepbound label (revised 08/2026), section 5.4, says treatment with Zepbound and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease. In pooled Studies 1 and 2 it reports cholelithiasis at 1.1% with Zepbound versus 1% with placebo, cholecystitis at 0.7% versus 0.2%, and cholecystectomy at 0.2% versus 0%.
The Foundayo label (orforglipron tablets, revised 07/2026), section 5.8, makes the same association statement for Foundayo and GLP-1 receptor agonists. For pooled Trials 1 and 2, it reports 1% cholelithiasis and 0.4% acute cholecystitis in Foundayo-treated patients; see the label’s table for the comparison with placebo.
The percentages come from different trials in different populations over different periods, so they are not a head-to-head comparison and should not be used to rank the medicines. Read them as the label’s description of what each program observed.
What gallbladder trouble feels like
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes a typical gallbladder attack as pain in the upper right abdomen that can last several hours and often follows heavy meals, usually in the evening or during the night. It advises seeking immediate medical attention for abdominal pain lasting several hours, nausea and vomiting, fever (even a low-grade one) or chills, yellowing of the skin or whites of the eyes, and tea-colored urine with light-colored stools. These can indicate serious infection or inflammation needing prompt treatment.
These symptoms overlap with pancreatitis, and gallstones are among the common causes of pancreatitis according to NIDDK. Our companion article on GLP-1 medicines and pancreatitis covers that warning.
Why weight loss and gallstones are linked, and why the label still flags the drug
The label’s own wording is careful. It acknowledges that substantial or rapid weight loss increases gallstone risk by itself, which is true of any approach that produces fast weight loss. It also says the difference between Wegovy and placebo persisted after accounting for how much weight patients lost, so weight loss alone does not appear to explain all of the signal. That is why the warning is attached to the medicine and not only to the weight change.
Questions to ask your prescriber
- Do I have known gallstones, or have I had gallbladder symptoms or surgery in the past?
- Which symptoms should lead me to call you the same day, and which need emergency care?
- If I develop upper right abdominal pain after meals, should I pause the medicine until I have been assessed?
- How do you want me to report episodes that settle on their own?
The labels do not contain an absolute contraindication for prior gallbladder disease in the sections we reviewed, so the decision rests on your history and your clinician’s judgment. For wider cautions, see who should not take an oral GLP-1, and for procedures involving sedation see GLP-1 medicines before surgery or anesthesia.
Common misunderstandings
- “It is only the weight loss, not the medicine.” Wegovy’s label says the excess persisted after accounting for weight loss.
- “A history of gallstones rules the medicine out.” The label sections reviewed do not say so. Discuss your history with your prescriber.
- “The numbers show which brand is safest.” The figures come from separate trials and cannot be compared directly.
- “Pain after meals is just indigestion.” Pain that lasts hours or sits in the upper right abdomen deserves assessment.
Questions people ask
What does the label tell clinicians to do if gallbladder disease is suspected?
The labels say gallbladder studies (or diagnostic studies) and appropriate clinical follow-up are indicated.
Do the labels say to stop the medicine for gallstones?
The gallbladder sections reviewed describe follow-up and testing rather than a discontinuation instruction. The pancreatitis sections are different, because they do say to discontinue if pancreatitis is suspected. Your prescriber decides what applies to you.
Is this more of a risk with fast weight loss?
The Wegovy label says substantial or rapid weight loss can increase gallstone risk. Talk to your prescriber about a pace of treatment that suits you.
Sources
- U.S. FDA labeling, Wegovy prescribing information (revised 06/2026), section 5.3, checked 6 October 2026.
- U.S. FDA labeling, Zepbound prescribing information (revised 08/2026), section 5.4, checked 6 October 2026.
- U.S. FDA labeling, Foundayo prescribing information (revised 07/2026), section 5.8, checked 6 October 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases, Symptoms & Causes of Gallstones, checked 6 October 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases, Symptoms & Causes of Pancreatitis, checked 6 October 2026.
Medical disclaimer. This article is informational and is not medical advice. If you have severe or persistent abdominal pain, fever or yellowing of the skin, seek urgent medical care. Do not start, stop or change a prescribed medicine without instructions from your prescriber.
Keep exploring our GLP-1 resources:
